证券日报网讯 11月24日晚间，一品红发布公告称，公司全资子公司广州一品红制药有限公司于近日收 到国家药品监督管理局核准签发的关于重酒石酸利斯的明口服溶液的《药品注册证书》。 （文章来源：证券日报） ...

华锋股份：筹划控制权变更股票停牌 11月24日午间，华锋股份（002806）发布公告称，公司股票自2025年11月24日（星期一）开市起停牌， 预计停牌时间不超过2个交易日。公司控股股东、实际控制人及董事长谭帼英于2025年11月22日与陈运 签署了《股权转让意向协议》，该事项可能导致公司控股股东、实际控制人发生变更。 资料显示，华锋股份成立于1995年8月，主营业务是新能源汽车电控及驱动系统的研发、生产、销售以 及技术服务，同时保持电极箔的研发、生产、销售。 所属行业：汽车–汽车零部件–底盘与发动机系统 科士达：董事拟减持不超过42.4万股公司股份 11月24日，科士达（002518）发布公告称，公司董事李春英计划自公告披露之日起15个交易日后的三个 月内，以集中竞价方式减持不超过42.4万股公司股份，占总股本的0.07%。 资料显示，科士达成立于1993年3月，主营业务是研发、生产及销售UPS、太阳能逆变器及UPS配套的 阀控式密封铅酸蓄电池。 所属行业：电力设备–其他电源设备Ⅱ–其他电源设备Ⅲ 金麒麟：拟每股派发现金红利0.1元 11月24日，金麒麟（603586）发布2025年季度权益分派实施公告，公 ...

一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核 准签发的关于重酒石酸利斯的明口服溶液的《药品注册证书》。根据核准的说明书，重酒石酸利斯的明 口服溶液适应症为：用于治疗轻、中度阿尔茨海默型痴呆的症状。 ...

一品红公告，全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于重酒 石酸利斯的明口服溶液的药品注册证书，根据核准的说明书，重酒石酸利斯的明口服溶液适应症为用于 治疗轻、中度阿尔茨海默型痴呆的症状。 (本文来自第一财经) ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监 督管理局核准签发的关于重酒石酸利斯的明口服溶液的《药品注册证书》。根据核准的说明书，重酒石 酸利斯的明口服溶液适应症为：用于治疗轻、中度阿尔茨海默型痴呆的症状。 ...

一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于重酒石酸利斯的 明口服溶液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：重酒石酸利斯的明口服溶液 英文名/拉丁名：Rivastigmine Bitartrate Oral Solution 主要成份：重酒石酸利斯的明 剂 型：口服溶液剂 证券代码：300723 证券简称：一品红 公告编号：2025-079 一品红药业集团股份有限公司 关于全资子公司获得重酒石酸利斯的明口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 注册分类：化学药品 3 类 规 格：120ml:0.24mg（按 C14H22N2O2计） 药品注册标准编号：YBH29112025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 生产企业地址：广州市经济技术开发区东区东博路 6 号 药品批准文 ...

Core Viewpoint - Yipin Hong (300723) faces significant challenges with a high-profile lawsuit claiming 528 million yuan in damages, compounding its ongoing financial struggles and regulatory issues [1][4][8] Financial Performance - In 2024, Yipin Hong reported its first loss since going public, with revenue declining by 42.07% to 1.45 billion yuan and a net loss of 540 million yuan, compared to a profit of 185 million yuan the previous year [5][6] - For the first three quarters of 2025, the company generated revenue of 814 million yuan, a year-on-year decrease of 34.35%, and reported a net loss of 136 million yuan [7][8] Legal Issues - The lawsuit from Huiyou International claims infringement of a patent related to a joint project initiated in 2014, with Yipin Hong asserting that the patent rights belong to a joint venture and that it has the right to use the patent [2][3] - The total amount involved in other undisclosed lawsuits against Yipin Hong is approximately 5.63 million yuan, indicating ongoing legal challenges [3] Regulatory Challenges - In 2024, Yipin Hong's subsidiary was penalized for collusion in drug procurement, resulting in the cancellation of its qualification and a financial loss of 266 million yuan, which significantly impacted its financial performance [1][5][8] Strategic Outlook - The company is pinning hopes on the new gout drug AR882, which has completed its Phase III clinical trials, but faces uncertainties regarding clinical data, market competition, and commercialization capabilities [8]

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 182.83%, but a recent decline in the last 20 and 60 days, indicating potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its IPO on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several other funds entering the top ten circulating shareholders [3]. Market Activity - On November 19, Yipinhong's stock price fell by 2.01% to 48.25 yuan per share, with a trading volume of approximately 49.77 million yuan and a turnover rate of 0.24%. The total market capitalization is 21.794 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

Core Points - The company Yipinhong announced the election of Ms. Huang Liangwen as the employee director of the fourth board of directors [2] Summary by Category Company Announcement - Yipinhong has officially elected Ms. Huang Liangwen to serve as the employee director on its fourth board of directors [2]

Group 1 - The core point of the article is that Yipin Hong (SZ 300723) held its 13th meeting of the fourth board of directors on November 18, 2025, to discuss the election of new members for the remuneration and assessment committee [1] - As of the report, Yipin Hong has a market capitalization of 22.2 billion yuan [3] Group 2 - For the year 2024, Yipin Hong's revenue composition is as follows: 96.78% from pharmaceutical manufacturing and 3.22% from pharmaceutical agency [2]